Study Indicates Potentized Drugs And Parent Drugs Behave Differently In Biological Interactions
This question whether potentized drugs interact with biological molecules in a way different from their parent drugs is very important in the scientific understanding of molecular processes involved in homeopathic potentization and therapeutics. There are many homeopaths believing that during potentization, the medicinal properties of drugs are some way or other transferred to the potentizing medium, and hence potentized medicines can interact with human organism in the same way as the original drugs.
On the contrary, DIALECTICAL HOMEOPATHY proposes that potentization involves a process of ‘molecular imprinting’, in which the spacial configuration of drug molecules are imprinted into the medium as 3-D nano cavities, which can act as recognition sites towards original drug molecules or other molecules similar in configuration. As per this view, potentized medicines contain only ‘molecular imprints’ of drug molecules, which are complementary in configuration to the drug molecules. When applied for therapeutic purpose, these molecular imprints bind to the pathogenic molecules, and not to the biological targets.
In order to prove this concept, we have to experimentally prove that potentized medicines can not interact with biological molecules in the same way as original drug molecules used for potentization.
Here I am reproducing a previously published report regarding such an experiment already conducted by a team of eminent scientists in Germany five years back. It is published in “The Journal of Alternative and Complementary Medicine. May 2006, 12(4): 359-365. doi:10.1089/acm.2006.12.359”
The team conducted this experiment to verify whether potentized HgCl2 (Mercurius corrosivus) affect the activity of Diastase and α-Amylase in a way similar to crude form of HgCl2.
Research team consisted of: 1. Claudia M. Witt, M.D. Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany. 2. Michael Bluth, M.D. Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany. 3. Stephan Hinderlich, Ph.D. Institute for Biochemistry and Molecular Biology, Charité University Medical Center, Berlin, Germany. 4. Henning Albrecht, Ph.D. Karl and Veronica Carstens-Foundation, Essen, Germany. 5. Rainer Lüdtke, M.Sc. Karl and Veronica Carstens-Foundation, Essen, Germany. 6. Thorolf E.R. Weisshuhn Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany. 7. Stefan N. Willich, M.D., M.P.H. Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany.
Their objective was to test for a stimulating or inhibiting effect of high potencies of the homeopathic remedy HgCl2 (Mercurius corrosivus) on two sugar hydrolases- (α-amylase from hog pancreas and diastase extract from winter barley)
High potencies of HgCl2 were produced using stepwise dilution plus shaking. Controls included potentized solvent (aqua bidestillata), equimolar dilutions without shaking, and enzyme-free references. Tested were potencies with dilution factors 1:200 (CC) on diastase extract from winter barley, and 1:100 (C) on α-amylase from hog pancreas. Enzyme activity was colorimetrically determined by Lugol’s iodine-starch reaction.
An inhibiting effect of HgCl2 on enzyme activities was observed only in low potencies and dilutions (which contained molecules of HgCl2). Statistically significant differences between potencies and controls were not found in randomized and blinded experiments.
This experimental design provided independent reproducible results of cell-free in vitro assays.However, it did not indicate an effect of potentized HgCl2 on hydrolases. The researchers conclusion was that demonstrating potency effects may require additional experimental features.
Reported experiments and the results they obtained may help us in designing and conducting further in vitro experiments to prove the hypothesis put forward by DIALECTICAL HOMEOPATHY regarding potentization.
HgCl2 is known in homeopathy as Merc Cor.
Crude HgCl2 is a known inhibitor of glucose hydrolases such as diastase and α-amylase.
Reported experiments show that similar to crude forms, lower dilutions of this compound also inhibits the hydrolyzing activity of those sugar hydrolase enzymes. Obviously, these lower dilutions contain molecules of HgCl2, and hence the inhibitory action on enzymes.
Same time, these experiments clearly showed that higher potencies of HgCl2 have no inhibitory action on those enzymes. That means, highly potentized HgCl2 cannot ‘mimic’ the original compound as expected by some theoreticians.
This finding, though considered by the researchers as a set back to their expectations, has serious implications in proving the concepts of DIALECTICAL HOMEOPATHY regarding potentization.
This experiment proves that through the potentization process, the properties of original drugs are not transferred to the potenizing medium in such a way so as to enable it to ‘mimic’ the original drugs.
We homeopaths know beyond any doubt that potentized HgCl2 or Merc Cor produces expected therapeutic effects when administered on the basis of principle of ‘similia similibus curentur’. That means, potentized HgCl2 contains some active principles having specific biochemical properties. Since the present experiments have shown that potentized HgCl2 cannot ‘mimic’ the biochemical properties of original compound, a logical and scientific explanation regarding the real molecular mechanism involved in potentization as well as therapeutic action becomes very much necessary.
Only possibility is ‘molecular imprinting’, as proposed by DIALECTICAL HOMEOPATHY.
Now, we have to repeat these in vitro experiment to verify whether higher potencies of HgCl2 can reactivate the enzymes already inhibited by lower potencies or crude forms of the same compound.